China-based Neowise Biotechnology has raised over RMB 200 million in a Series B financing round co-led by Apricot Capital and an undisclosed industry fund. The proceeds will advance the clinical development of its T-cell receptor-engineered T-cell (TCR-T) therapies for solid tumours and progress its preclinical pipeline. The company, founded in 2020, has developed a high-throughput platform for discovering native, high-affinity TCR sequences against tumour antigens.

Neowise's lead candidate, NW-101C, is a TCR-T cell therapy targeting PRAME and is the first product against this target to enter clinical trials in China. It is currently in Phase I studies for various solid tumours. Another candidate, NW-301V, which targets the KRAS G12V mutation, presented positive preliminary data at the 2025 ESMO congress, showing a 50% objective response rate (ORR) and a 100% disease control rate in a subset of patients with advanced colorectal and pancreatic cancers. The funding will support the clinical and commercial advancement of these programs.

PharmCube's NextBiopharm® database lists over 300 TCR T therapies under development globally. Click here to request a free trial for NextBiopharm®.